Kamada

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kamada reports robust earnings, eyes global expansion and clinical milestones

Kamada's strong financial performance, strategic acquisitions, and global expansion efforts position the company for continued growth and market success.
While facing challenges in maintaining growth momentum and operational efficiency, Kamada's focus on innovation and market expansion presents significant opportunities for future development.
Investors should monitor Kamada's progress in clinical trials, product diversification, and international market penetration to assess the company's long-term growth potential and market positioning.

Kamada secures $60M investment, targets 35% revenue growth in 2023

Kamada's Q1 2023 performance showed revenue and EBITDA growth, supported by strategic investments and regulatory approvals. While facing rising expenses and financial challenges, the company aims for significant revenue growth in 2023 through market expansion and trial acceleration.

Kamada (KMDA) reports strong Q2 earnings and secures $60M investment

Kamada (KMDA) delivered robust financial results in Q2 2023, with significant revenue growth and positive EBITDA performance.
The company's strategic investments, diverse product pipeline, and regulatory progress underscore its potential for future growth and market expansion.
Stable cash position, operational efficiency, and ongoing clinical advancements position Kamada favorably in the biopharmaceutical industry.
Overall, Kamada's Q2 performance and future outlook reflect a promising trajectory for sustained growth and value creation for shareholders.

Kamada reports robust Q3 earnings, eyes growth through clinical trials

Kamada's Q3 2023 earnings call highlighted strong financial performance, debt-free status, and strategic initiatives for future growth. The company's focus on product development, clinical trials, and board expertise positions it well for continued success and profitability.

Kamada reports robust 2023 earnings, eyes growth through strategic initiatives

Kamada's strong financial performance in 2023 and positive outlook for 2024 underscore the company's growth trajectory and market positioning.
While facing challenges such as rising operating expenses, Kamada's focus on innovation, market expansion, and strategic partnerships presents opportunities for sustained growth.
Maintaining a robust balance sheet and advancing key clinical trials reflect Kamada's commitment to financial stability, product development, and long-term value creation.

Kamada doubles profitability in Q1 2024, eyes revenue growth

Kamada delivered robust financial performance in Q1 2024, with doubled profitability and revenue growth driven by key products. The company's strategic initiatives, including product launches and clinical trial progress, position it well for future success. While facing cost pressures, Kamada's strong cash position and focus on innovation present opportunities for sustained growth.

Kamada excels in Q2, eyes global expansion and clinical milestones

Kamada's strong financial performance in Q2 2024 and the first half of the year, coupled with reaffirmed full-year guidance, reflect a positive growth trajectory and financial stability.
The company's strategic focus on organic growth, M&A activities, and clinical trials positions it well to capitalize on market opportunities and drive future revenue expansion.
While challenges such as dividend policy, regulatory timelines, and market competition exist, Kamada's proactive approach to business development and global partnerships underscores its commitment to sustained growth and innovation.

Kamada reports strong Q3 earnings, eyes growth in clinical trials

Kamada's Q3 2024 earnings call highlighted robust financial performance, increased guidance, and strategic initiatives driving growth and market expansion.
With a strong balance sheet, ongoing clinical trials, and expansion plans, Kamada is well-positioned to capitalize on market opportunities and sustain growth momentum.
While challenges such as market competition and integration risks exist, Kamada's proactive approach to innovation, partnerships, and operational efficiency bodes well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Call Start: 08:30 January 1, 0000 9:52 AM ET Kamada Ltd. (NASDAQ:KMDA ) Q3 2024 Earnings Conference Call November 13, 2024, 08:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Greetings, and welcome to the Kamada Ltd.

Kamada Ltd. (KMDA) Q3 2024 Earnings Call Transcript

REHOVOT, Israel and HOBOKEN, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its plasma collection operations with the opening of a new plasma collection center in Houston, TX. The new 12,000 square foot center is operated by Kamada's wholly owned subsidiary, Kamada Plasma, and is planned to support over 50 donor beds with an estimated total collection capacity of approximately 50,000 liters annually.

Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston

Kamada Ltd. (NASDAQ:KMDA ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Troy Williams - LifeSci Advisors Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Greetings, and welcome to Kamada Limited Second Quarter 2024 Earnings Conference Call.

Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript

REHOVOT, Israel, and HOBOKEN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the second quarter and first half ended June 30, 2024, prior to the open of the U.S. financial markets on Wednesday, August 14, 2024.

Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024

CASI Pharmaceuticals

Valneva SE

What could be better than viable enterprises within the biotechnology industry? Try biotech stocks under $10.

3 Promising Biotech Stocks You Can Pick Up for Less Than $10

Kamada Ltd. (NASDAQ:KMDA ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors, LLC Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Good morning, ladies and gentlemen, and welcome to the Kamada Limited First Quarter 2024 Earnings Conference Call.

Kamada Ltd. (KMDA) Q1 2024 Earnings Call Transcript

REHOVOT, Israel and HOBOKEN, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for three months ended March 31, 2024.

Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance

REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2024, prior to the open of the U.S. financial markets on Wednesday, May 8, 2024.

Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Results Earnings Conference Call March 6, 2024 8:30 AM ET

Kamada Ltd. (KMDA) Q4 2023 Earnings Call Transcript

REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer.

Kamada Issues 2024 CEO Letter to Shareholders

REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months and year ended December 31, 2023.

Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability

REHOVOT, Israel, and HOBOKEN, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd.

Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024

Kamada is a profitable specialty plasma company with a strong balance sheet and significant capital available for investment. The company has announced an expanded commercial agreement for its anti-rabies drug Kedrab including a minimum revenue guarantee for the next four years. The new deal significantly derisks the Kamada investment case by locking in growth for one of the company's largest revenue streams.

Kamada: Kedrion Deal Locks In Growth

NEW YORK, NY, December 07, 2023 – PRISM MarketView, a leading provider of unbiased market insight and company news, highlights Kamada Ltd.

PRISM MarketView Biotech Index Top Mover Spotlight: Kamada (KMDA)

Since 2018 Kedrion has had exclusive distribution rights in the US for KEDRAB®, a Human Rabies Immune Globulin (HRIG) developed in partnership with Kamada Ltd. New agreement becomes effective in January 2024 and includes potential expansion of Kedrion's distribution of KEDRAB® in additional territories beyond the US Rabies is a global public health concern that is responsible for more than 59,000 human deaths per year in the world; an estimated 60,000 Americans receive Rabies post exposure prophylaxis each year Kedrion confirms its commitment to fighting Rabies and other serious and life-threatening diseases and conditions CASTELVECCHIO PASCOLI, Italy , Dec. 7, 2023 /PRNewswire/ --  Kedrion Biopharma , a leading global biopharmaceutical company that develops, manufactures and commercializes therapeutic products derived from blood plasma , announces the execution of a binding memorandum of understanding with Kamada Ltd.

KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®

REHOVOT, Israel and HOBOKEN, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the execution of a binding memorandum of understanding with Kedrion for the amendment and extension of the KEDRAB® U.S. distribution agreement between the parties. Within the first four years of the eight-year term, which begins in January 2024, Kedrion will purchase minimum quantities of KEDRAB with revenues to Kamada of approximately $180 million.

Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years

AGNC Investment

Crocs

Domino's Pizza

Federated Hermes

Groupon

Gravity Co

Gray TV

Hims & Hers Health

JD.com

Malibu Boats

Methanex

OneMain Hld

PayPal

Semrush Holdings

SpringWorks Therapeutics Inc

Tarsus Pharmaceuticals

Tecnoglass

Vanguard S&P 500 ETF

WD-40

Wabash National

In November, we welcomed 24 new analysts who published their first article on Seeking Alpha. This series highlights and welcomes these newcomers to our ranks of analysts who share their unique insights and perspectives as well as some of their top investing ideas. We've compiled all of their firsts here for your review and to showcase the new perspectives being offered on the platform.

Celebrating Seeking Alpha's New Analysts - November 2023 Edition

Kamada is a profitable specialty plasma company with a strong balance sheet and significant capital available for investment. The company is expected to grow EBITDA significantly in the coming years through its existing business and potential acquisitions or licensing of new products. Limited downside outside Israel country risk.

Kamada: Solid Specialty Plasma Play

Kamada Ltd. (NASDAQ:KMDA ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Good day ladies and gentlemen and welcome to Kamada Ltd.

Kamada Ltd. (KMDA) Q3 2023 Earnings Call Transcript

REHOVOT, Israel and HOBOKEN, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three and nine months ended September 30, 2023.

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and first nine months ended September 30, 2023, prior to the open of the U.S. financial markets on Monday, November 13, 2023.

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

REHOVOT, Israel, and HOBOKEN, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that while circumstances in Israel are evolving, the Company continues to conduct its business operations in Israel with no effect on business continuity, and its global supply of products is not expected to be interrupted. Kamada will provide further updates if and when material events so warrant.

Kamada Provides Corporate Update on its Israel Operations

Compugen

Gamida Cell Ltd

Protalix Biotherapeutics

Taro Pharmaceutical Industries

Teva Pharmaceutical

Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced shareholder approval and planned closing of the previously announced $60 million private placement (the “Private Placement”) with FIMI Opportunity Funds (“FIMI”), the leading private equity firm in Israel and a large existing Kamada shareholder.

Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

Kamada Ltd. (NASDAQ:KMDA ) Q2 2023 Earnings Conference Call August 16, 2023 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Amir London - CEO Chaime Orlev - CFO Conference Call Participants Annabel Samimy - Stifel Operator Greetings.

News for Kamada Stock (KMDA)